Proactive Investors - Run By Investors For Investors

First data for Redx Pharma’s RXC006 fibrosis candidate shows compound has “great potential”

The data showed RXC006 was able to suppress the Wnt pathway, which is widely believed to be heavily involved in the scarring process associated with lung fibrosis
fibrosis
Along with cancer, fibrosis is one of Redx’s core focus areas

The first pre-clinical data for Redx Pharma Plc’s (LON:REDX) RXC006 drug candidate has suggested that the compound has “great potential” as a fibrosis treatment.

RXC006 is what’s known as a Porcupine inhibitor. They work by dialling down the Porcupine protein, which is the control switch for the Wnt pathway – widely believed to be heavily involved in the scarring process in the lung typical of idiopathic pulmonary fibrosis.

READ: Redx hails new fibrosis candidate

This first batch of in-vivo data showed that the compound was “highly effective” in suppressing the Wnt pathway and lung fibrosis.

Suppression of both liver and kidney fibrosis has also been shown in animal models.

“The data suggests that RXC006 has great potential to treat fibrosis in human patients,” said chief scientific officer Richard Amer.

“Redx are progressing RXC006 towards the clinic for the treatment of Idiopathic Pulmonary Fibrosis and plan to initiate first in man clinical trials during 2020.”

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
Cameron Durrant
March 04 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use